GSK reports positive Phase III results of mepolizumab for COPD

GlaxoSmithKline (GSK) has reported positive results from two Phase III clinical trials of mepolizumab to treat patients with eosinophilic chronic obstructive pulmonary disease (COPD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news